^
    Back
    Association details:
    Biomarker:BAIAP2-ROS1 fusion
    Cancer:Lung Adenocarcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Onco Targets Ther
    Title:

    Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report

    Published date:
    07/28/2022
    Excerpt:
    ...we identified a novel BAIAP2-ROS1 fusion in a 71-year-old non-smoking female patient with stage IVB lung adenocarcinoma….The patient subsequently received crizotinib and showed significant tumor reduction until 17 months, who got benefit from targeted therapy.
    DOI:
    https://doi.org/10.2147/OTT.S372134